About: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1998 (uk) article scientifique publié en 1998 (fr) im Juni 1998 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q59647356-2C2A3D29-2526-4059-93C9-A6EA8DC99D1E
publication date	1998-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59647356-40A93E7C-8DE8-420A-B60C-37B523B3F0CC
language of work or name	English
author name string	wds:Q59647356-38299D95-A27F-476F-80B8-4E3625A932E2 wds:Q59647356-6A93A973-C7A9-4E7D-889A-11C4B2669A1F wds:Q59647356-6B0FCF32-E848-4639-A029-81D022F37D15 wds:Q59647356-8B570064-8012-47F4-92C2-0842CA16514D wds:Q59647356-94C8A569-39FB-4CCC-835B-5F97912D7D48 wds:Q59647356-AF102C44-7DBF-4AD5-B407-C5591C8AA835 wds:Q59647356-BE7C6884-6DC6-4F66-9D43-A9580571777E wds:Q59647356-D5600900-49AD-4F12-AA64-96BA2836734F wds:Q59647356-D66A3381-C54E-49A3-942A-CC5598312872 wds:Q59647356-DC68A82C-423C-4FE9-90A3-EC0247777624
author name string	E Eisenhauer M Roy B Zee G Stuart P Drouin S Beare P Hoskins R Grimshaw P Bryson V Capstick
rdfs:label	Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (en) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (nl)
skos:prefLabel	Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (en) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (nl)
name	Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (en) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (nl)
title	wds:Q59647356-6776686C-0E69-4B12-8487-D8A97A08D9B8
title	Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study (en)
page(s)	wds:Q59647356-D3F9C6A9-45DA-456F-8EB6-F91AB524265D
page(s)	2233-7
instance of	wds:Q59647356-85F2711C-646B-4072-8776-C218AF0AD12A
instance of	scholarly article
main subject	wds:Q59647356-131D09E2-3148-465A-80EE-8EB7683E3E5A wds:Q59647356-4239267D-D36C-4E83-A81E-41212FC76295 wds:Q59647356-CC54180C-6A2B-4564-8C08-E0E0861488A5
main subject	ovarian neoplasm Malawi phase II clinical trial
PubMed ID	wds:Q59647356-C9DA34F9-6C54-4434-9079-4530A4F44FEB
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9626225
PubMed ID	9626225
published in	wds:Q59647356-4D182315-C0CE-495E-BB3E-AE0A414FA57D
published in	Journal of Clinical Oncology
issue	wds:Q59647356-3A7A2559-6D38-45B7-ABDC-D6C40F71DDB0
volume	wds:Q59647356-8D6C39A8-BCC8-4658-80E0-37C1A48AD502
issue	6
volume	16
DOI	wds:Q59647356-636B6CEB-E47C-486D-BD47-156F04FA309C
DOI	http://dx.doi.org/10.1200/JCO.1998.16.6.2233
DOI	10.1200/JCO.1998.16.6.2233
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59647356
is cites work of	Camptothecins: a review of their development and schedules of administration Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma Weekly topotecan for recurrent platinum resistant ovarian cancer Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer Topotecan for ovarian cancer Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer Initial testing of topotecan by the pediatric preclinical testing program. Clinical experience with topotecan in relapsed ovarian cancer Weekly topotecan in the management of ovarian cancer Optimal sequencing in the treatment of recurrent ovarian cancer OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Phase III data on Caelyx in ovarian cancer Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Clinical trials and progress with paclitaxel in ovarian cancer Topotecan. A review of its potential in advanced ovarian cancer Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. DNA-based drug interactions of cisplatin A phase I and pharmacokinetic study of intraperitoneal topotecan Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study Workshop: options for therapy in ovarian cancer 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software